NEW YORK: Flatiron Health, a leading healthtech company dedicated to improving cancer care and advancing research using real-world data (RWD), today announced a milestone of over 1,000 research publications utilizing Flatiron’s electronic health record-derived RWD. This achievement reinforces Flatiron's position as a pioneer in the application of RWD and was made possible through its history of collaboration to support rigorous research projects across the oncology ecosystem, including the 20+ top global developers of oncology therapeutics, academic institutions, policy groups, and regulators around the world.

Founded in 2012, Flatiron’s high-quality RWD and real-world evidence (RWE) have transformed data captured during routine care into actionable evidence, improving patient outcomes, supporting FDA regulatory approvals, delivering clinical insights, informing policy, and advancing the company’s mission to improve and extend lives by learning from the experience of every person with cancer. Flatiron’s RWD has played a role in generating high-impact evidence, providing expanded therapy options for men with breast cancer, more convenient dosing regimens for people with certain EGFR mutations—meaning less time in treatment, and defined timelines for progression-free lung cancer patients to discontinue immunotherapy treatments after two years.

Flatiron’s publications have contributed to landmark research for people with cancer, representing all of the National Cancer Institute's most common cancer types and many more rare diseases, improving the understanding of solid tumors and hematologic malignancies globally. Research led and authored by Flatiron, as well as studies conducted by collaborators using Flatiron’s RWD, have been published in 142 unique peer-reviewed journals including The Journal of the American Medical Association and presented at prestigious oncology conferences worldwide, including over 350 presentations at the scientific meetings of the American Society of Clinical Oncology (ASCO), and additional high-impact research at the American Society of Hematology (ASH), European Society for Medical Oncology (ESMO), and The Professional Society for Health Economics and Outcomes Research (ISPOR), to name a few.

Flatiron-led research has been cited over 4,000 times across peer reviewed publications, driving forward the industry’s understanding of RWD and its potential for high-quality evidence generation. Flatiron has also lent expertise across more than 20 manuscripts in collaboration with leading international regulatory bodies and policy organizations, including FDA and NICE.

“Reaching this milestone of 1,000 publications underscores the value and quality of our real-world data and expertise, unlocking the power of evidence-based medicine, so every person’s experience can inform and improve outcomes for future patients,” said Jonathan Kish, VP, Head of Research Sciences at Flatiron Health. “Flatiron’s in-house services and experts provide partners across the healthcare ecosystem with high-quality data, as well as study design, analytics, and reporting support for the critical retrospective and prospective research making an impact on our understanding of cancer care.”

Beyond the volume of Flatiron’s published research, the company has pioneered novel RWD methods—such as AI for the extraction of biomarkers and real-world endpoints like tumor response from unstructured data—and RWE approaches for observational research, including comparative effectiveness, external control arms, and assessment of social determinants of health and their related cancer inequities.

Flatiron continues to drive innovation in cancer research. Most recently, the company’s launch of AI-powered Panoramic datasets, including breast and lung cancer, unlocks over 4M de-identified patient records and 1.5B data points in Flatiron’s network for use in research across the patient journey, including commercial tracking and analysis for target populations, emerging and standard of care biomarker data, and safety and outcomes analysis. These solutions are enabling the next generation of cancer research, providing large scale datasets to power studies not previously possible that answer critical questions across the healthcare ecosystem.

About Flatiron Health

Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients’ real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group.

Fonte: Business Wire